Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?

被引：45
|
作者：
Kudzi, William [1 ,2 ]
Dodoo, Alexander N. O. [2 ]
Mills, Jeremy J. [1 ]
机构：
[1] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England
[2] Univ Ghana, Sch Med, Accra, Ghana
来源：
BMC MEDICAL GENETICS | 2010年 / 11卷
关键词：
SINGLE-NUCLEOTIDE POLYMORPHISMS; MULTIDRUG-RESISTANCE GENE; ONCHOCERCIASIS-ENDEMIC FOCI; P-GLYCOPROTEIN; TRANSPLANT RECIPIENTS; MULTIPLE TREATMENTS; SEQUENCE DIVERSITY; CYTOCHROME-P450; 3A; LIVER-MICROSOMES; DRUG TRANSPORTER;
D O I：
10.1186/1471-2350-11-111
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Background: Ivermectin, a substrate of multidrug resistance (MDR1) gene and cytochrome P450 (CYP) 3A4, has been used successfully in the treatment of onchocerciasis in Ghana. However, there have been reports of suboptimal response in some patients after repeated treatment. Polymorphisms in host MDR1 and CYP3A genes may explain the observed suboptimal response to ivermectin. We genotyped relevant functional polymorphisms of MDR1 and CYP3A in a random sample of healthy Ghanaians and compared the data with that of ivermectin-treated patients with a view to exploring the relationship between suboptimal response to ivermectin and MDR1 and CYP3A allelic frequencies. Methods: Using PCR-RFLP, relevant polymorphic alleles of MDR1 and CYP3A4 genes were analysed in 204 randomly selected individuals and in 42 ivermectin treated patients. Results: We recorded significantly higher MDR1 (3435T) variant allele frequency in suboptimal responders (21%) than in patients who responded to treatment (12%) or the random population sample (11%). CYP3A4*1B, CYP3A5*3 and CYP3A5*6 alleles were detected at varied frequencies for the sampled Ghanaian population, responders and suboptimal responders to ivermectin. CYP3A5*1/CYP3A5*1 and CYP3A5*1/CYP3A5*3 genotypes were also found to be significantly different for responders and suboptimal responders. Haplotype (*1/*1/*3/*1) was determined to be significantly different between responders and suboptimal responders indicating a possible role of these haplotypes in treatment response with ivermectin. Conclusion: A profile of pharmacogenetically relevant variants for MDR1, CYP3A4 and CYP3A5 genes has been generated for a random population of 204 Ghanaians to address the scarcity of data within indigenous African populations. In 42 patients treated with ivermectin, difference in MDR1 variant allele frequency was observed between suboptimal responders and responders.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups
    Li, D.
    Zhang, G-L.
    Lou, Y-Q.
    Li, Q.
    Wang, X.
    Bu, X-Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (01) : 89 - 95
  • [42] CYP3A4 and CYP3A5 genotyping by pyrosequencing
    Garsa, AA
    McLeod, HL
    Marsh, S
    BMC MEDICAL GENETICS, 2005, 6
  • [43] Comparison of CYP3A4 and CYP3A5 in Drug Metabolism and Drug Interactions
    Li, Shuanmei
    Liu, Duan
    Zhu, Juanli
    Cui, Yan
    Zhou, Ruimin
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32
  • [44] Genetic Polymorphisms in CYP3A5 and MDR1 Genes and Their Correlations With Plasma Levels of Tacrolimus and Cyclosporine in Renal Transplant Recipients
    Mendes, J.
    Martinho, A.
    Simoes, O.
    Mota, A.
    Breitenfeld, L.
    Pais, L.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (03) : 840 - 842
  • [45] CYP3A4,CYP3A5和MDR1基因多态性对环孢素处置的影响
    胡永芳
    周宏灏
    中国药理学通报, 2005, (03) : 257 - 261
  • [46] CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies
    Engman, HA
    Lennernäs, H
    Taipalensuu, J
    Otter, C
    Leidvik, B
    Artursson, P
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) : 1736 - 1751
  • [47] Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques
    Uno, Yasuhiro
    Matsushita, Akinori
    Osada, Naoki
    Uehara, Shotaro
    Kohara, Sakae
    Nagata, Ryoichi
    Fukuzaki, Koichiro
    Utoh, Masahiro
    Murayama, Norie
    Yamazaki, Hiroshi
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 209 - 214
  • [48] Effects of CYP3A4 and CYP3A5 polymorphisms on cholesterol responses to atorvastatin.
    Langace, T. Y.
    Burkley, B.
    Gong, Y.
    Zineh, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S89 - S89
  • [49] Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients
    Li, Jia-li
    Liu, Shu
    Fu, Qian
    Zhang, Yu
    Wang, Xue-ding
    Liu, Xiao-man
    Liu, Long-shan
    Wang, Chang-xi
    Huang, Min
    PHARMACOGENOMICS, 2015, 16 (12) : 1355 - 1365
  • [50] Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population
    Mutawi, Thuraya M.
    Zedan, Mohamed M.
    Yahya, Raida S.
    Zakria, Mahmoud M.
    El-Sawi, Mamdouh R.
    Gaedigk, Andrea
    PHARMACOGENOMICS, 2021, 22 (06) : 323 - 334
12345